INTRODUCTION
============

Presynaptic voltage-gated Ca~v~2.1 (P/Q-type), Ca~v~2.2 (N-type), and Ca~v~2.3 (R-type) voltage-gated calcium channels (VGCCs) mediate nerve-evoked transmitter release. Their modulation by G protein--coupled receptors (GPCRs) is a key factor in controlling neuronal excitability at central and peripheral synapses ([@bib39]; [@bib60]; [@bib63]; [@bib31]). Multiple GPCR-mediated pathways converge on VGCCs, but Ca~v~2.3 channels are less susceptible to direct G protein βγ dimer modulation than Ca~v~2.1 or Ca~v~2.2 ([@bib57]), a finding attributed to differences between the N terminus, domain I, and the I--II intracellular linker of Ca~v~2.3 and Ca~v~2.2 channels ([@bib59]; [@bib58]). Nevertheless, carbachol, somatostatin, ATP, and adenosine inhibit exogenous Ca~v~2.3 channels via endogenous receptors in human embryonic kidney (HEK) cells ([@bib43]). Interestingly, carbachol, a muscarinic receptor agonist, stimulates or inhibits Ca~v~2.3 currents by distinct signaling pathways in HEK cells ([@bib5]), whereas the D2 dopamine receptor agonist quinpirole ([@bib46]) and µ opioid receptor agonist DAMGO ([@bib45]) inhibit Ca~v~2.3 currents in the *Xenopus laevis* oocyte system. Electrophysiological data suggest that baclofen, a derivative of γ-aminobutyric acid (GABA), inhibits R-type currents in the rat medial nucleus ([@bib63]) and locus coeruleus neurons ([@bib14]).

VGCCs are associated with a wide range of pathologies, including pain, and the value of selectively targeting Ca~v~2 channels for neuropathic pain treatment is recognized ([@bib3]; [@bib50]). We have shown that α-conotoxin Vc1.1, a small venom peptide from *Conus victoriae*, inhibits Ca~v~2.2 channels via GABA type B (GABA~B~) receptors (GABA~B~Rs) in rodent dorsal root ganglion (DRG) neurons ([@bib13]; [@bib12]) and the HEK expression system ([@bib19]). We also demonstrated that Vc1.1 can be used as an analgesic in rat models of neuropathic pain ([@bib36]). Ca~v~2.3 channels are also present in various nociceptors ([@bib27], [@bib28]) and contribute to pain behavior control by spinal and supraspinal mechanisms ([@bib53]; [@bib61]). However, Ca~v~2.3 modulation via GABA~B~Rs is incompletely characterized and has not been reconstituted in any heterologous expression system. Moreover, few drugs or toxins have specific Ca~v~2.3 inhibitory effects ([@bib56]).

In this study, we hypothesized that α-conotoxin Vc1.1 can modulate Ca~v~2.1 and Ca~v~2.3 channels via GABA~B~R activation. We designed experiments to examine the mechanisms of VGCC Ba^2+^ current (I~Ba~) inhibition by baclofen and Vc1.1, with emphasis on voltage-dependent (VD) and voltage-independent (VI) pathways, which may be present in these cells. Our data show that Vc1.1 only inhibits Ca~v~2.3 channels, despite baclofen efficiently inhibiting both Ca~v~2.1 and Ca~v~2.3 channels. Using site-directed mutagenesis in combination with functional expression in HEK cells, we demonstrate that c-Src phosphorylation of specific tyrosine residues in the α~1~ subunit C terminus is sufficient to mediate Vc1.1 inhibition of Ca~v~2.3 channels. A preliminary report of these results, in part, has been presented in abstract form (Berecki, G., J.R. McArthur, and D.J. Adams. 2013. Australian Neuroscience Society Inc. 33rd Annual Meeting. Abstr. ORAL-03-03).

MATERIALS AND METHODS
=====================

Cell culture, clones, and transfections
---------------------------------------

HEK cells containing the SV40 large T antigen (HEK-293T) were cultured at 37°C in 5% CO~2~ in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% (vol/vol) fetal bovine serum (Invitrogen), 50 IU/ml penicillin, and 50 µg/ml streptomycin (Invitrogen). HEK-293 cells, stably expressing human Ca~v~2.1 (P/Q-type) channel α~1A-2~ splice variant (GenBank accession no. [AF004883](AF004883)) or human Ca~v~2.3c (R-type) channel α~1E-3~ splice variant (also called α~1E-c~; GenBank accession no. [L29385](L29385)), were obtained from Merck and cultured according to procedures described previously ([@bib21]). Both cell lines express human α~2b~δ-1 (GenBank accession no. [M76559](M76559)) and human β~3a~ (RefSeq accession no. [NM_000725](NM_000725)) auxiliary subunits, and the human KCNJ4 (Kir2.3; GenBank accession no. [U07364](U07364)) channel ([@bib21]).

The human Ca~v~2.1 (P/Q-type) channel, α~1A~, transcript variant 5 (RefSeq accession no. [NM_001174080](NM_001174080)), cloned into pCMV plasmid, was provided by J. Striessnig (University of Innsbruck, Innsbruck, Austria). The human Ca~v~2.3d (R-type) channel (fetal brain α~1E-d~, splice variant L27745) was provided by T. Schneider (University of Cologne, Cologne, Germany). The wild-type human Ca~v~2.3c (α~1E-c~) channel (GenBank accession no. [L29385](L29385)) and mutant Ca~v~2.3c channels, α~1E-c~ (Y1761F) and α~1E-c~ (Y1765F), all cloned into pCDNA3.1 vectors, were purchased from GenScript USA Inc. The α~1E-d~ splice variant is identical in amino acid sequence to α~1E-c~, except for a 43--amino acid segment (insert III or exon 46) at the C terminus of the α~1E-d~ channel ([@bib49]). Human α~2b~δ-1 (RefSeq accession no. [NM_000722](NM_000722)) and human β~3~ channel subunits, transcript variant 1 (RefSeq accession no. [NM_000725](NM_000725)), were purchased from OriGene Technologies, Inc. Site-directed mutagenesis of the wild-type human Ca~v~2.3d (α~1E-d~) channel, resulting in α~1E-d~ (Y1761F) or α~1E-d~ (Y1765F), and site-directed mutagenesis of the wild-type human Ca~v~2.1 (α~1A-5~) channel, resulting in α~1A-5~ (L1852T) or α~1A-5~ (Q1852E), was performed with the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies), using the following oligonucleotides: Ca~v~2.3(Y1761F)-for, GCATGTGGCCGCATCCATTTCACTGAGATGTATGAAATG; Ca~v~2.3(Y1761F)-rev, CATTTCATACATCTCAGTGAAATGGATGCGGCCACATGC; Ca~v~2.3(Y1765F)-for, CATTACACTGAGATGTTTGAAATGCTGACTCTC; Ca~v~2.3(Y1765F)-rev, GAGAGTCAGCATTTCAAACATCTCAGTGTAATG; Ca~v~2.1(L1852T)-for, GGCCGCATGCCTTACACGGACATGTATCAGATG; Ca~v~2.1(L1852T)-rev, CATCTGATACATGTCCGTGTAAGGCATGCGGCC; Ca~v~2.1(Q1856E)-for, CTTACCTGGACATGTATGAGATGCTGAGACACATGTC; Ca~v~2.1(Q1856E)-rev, GACATGTGTCTCAGCATCTCATACATGTCCAGGTAAG.

For all primers, sense and antisense orientations are denoted as "for" and "rev," respectively. The names reflect the position of the tyrosine to be mutated to a phenylalanine (Ca~v~2.3), leucine to threonine (Ca~v~2.1), or glutamine to glutamic acid (Ca~v~2.1). All mutations were verified by automated DNA sequencing (Australian Genome Research Facility).

HEK cells stably expressing Ca~v~2.1 or Ca~v~2.3c channels were transiently cotransfected with plasmid cDNAs encoding human GABA~B~R1 (RefSeq accession no. [NM_001470](NM_001470); 3 µg; OriGene Technologies, Inc.), human GABA~B~R2 (RefSeq accession no. [NM_005458](NM_005458); 3 µg; OriGene Technologies, Inc.), and enhanced green fluorescent protein (eGFP) reporter gene construct (1 µg; provided by J.W. Lynch, The University of Queensland, Brisbane, Australia), using the calcium phosphate precipitation method ([@bib34]). In separate experiments, pRC-CMV/Src encoding wild-type mouse c-Src or pRC-CMV/Src(K295R/Y527F) double mutant mouse c-Src cDNA (provided by J. Ulrich, University of Iowa, Iowa City, IA) was also included in the above transfection mixture. The K295R mutation in the ATP-binding site inactivates the kinase, whereas the Y527F mutation abolishes intramolecular interactions between the C-terminal tail and the SH2 domain ([@bib30]).

HEK-293T cells were transiently cotransfected with plasmid cDNAs encoding human Ca~v~2.1 channel transcript variant 5 (5 µg) or wild-type or mutant human Ca~v~2.3d channels (5 µg), human α~2b~δ-1 (5 µg) and human β~3~ (5 µg) auxiliary subunits, human GABA~B~R1 (3 µg), human GABA~B~R2 (3 µg), and eGFP (1 µg). In a separate series of experiments, HEK-293T cells were transiently cotransfected with plasmid cDNAs encoding rabbit Ca~v~2.1 channel (RefSeq accession no. [NM_001101693](NM_001101693); 5 µg; provided by F. Meunier, The University of Queensland, St. Lucia, Australia), rat α~2~δ-1 (5 µg; provided by G.W. Zamponi, University of Calgary, Calgary, Canada) and rat β~3~ (5 µg; provided by D. Lipscombe, Brown University, Providence, RI) auxiliary subunits; human GABA~B~R1 (3 µg) and human GABA~B~R2 (3 µg); and eGFP (1 µg). After transfection, cells were plated on glass coverslips and incubated at 37°C in 5% CO~2~ for 6 h. Transfection medium was then replaced with culture medium, and cells were incubated at 30°C in 5% CO~2~.

Electrophysiology
-----------------

Experiments were performed 3--5 d after transfection, using the whole-cell patch-clamp technique. Currents through calcium channels were recorded using barium (Ba^2+^) as the charge carrier. Cells expressing the proteins of interest were superfused with a solution containing (mM): 110 NaCl, 10 BaCl~2~, 1 MgCl~2~, 5 CsCl, 30 TEA-Cl, 10 [d]{.smallcaps}-glucose, and 10 HEPES, pH 7.4 with TEA-OH, at ∼600 µl/min. Fire-polished borosilicate patch pipettes with tip resistance values of 2--3 MΩ were filled with an intracellular solution containing (mM): 125 K-gluconate, 2 MgCl~2~, 5 EGTA, 5 NaCl, 4 MgATP, and 10 HEPES, pH 7.25 with CsOH. In a series of experiments, EGTA was included in the intracellular solution at a concentration of 0.5 or 10 mM. GTP was not used in the intracellular solution to prevent I~Ba~ rundown caused by activation of signaling pathways when the whole-cell recording configuration was established ([@bib52]). To minimize endogenous currents, the osmolarity of solutions was adjusted with sucrose (310-mOsm extracellular, slightly hypertonic with respect to the 295-mOsm intracellular solution).

Electrophysiological recordings were performed at room temperature (23--25°C) using Multiclamp 700B amplifiers (Molecular Devices) controlled by Clampex 9.2/DigiData 1332 acquisition systems. I-V relationships were recorded from a holding potential (HP) of −80 mV using 100-ms depolarizations from −45 to +50 mV, in 5-mV increments. Peak I~Ba~ was measured for each step and normalized to the cell's maximal current. Normalized currents were averaged across cells and plotted (mean ± SEM) as a function of voltage. Test depolarizations to 10 mV (in cells coexpressing Ca~v~2.3 channels and GABA~B~Rs) or 15 mV (in cells coexpressing Ca~v~2.1 channels and GABA~B~Rs) of 150-ms duration were applied at a frequency of 0.1 Hz from an HP of −80 mV, where I~Ba~ was evaluated in the absence and presence of various compounds.

VD relief of the inhibition was assessed from an HP of −80 mV, using a protocol with a 20-ms prepulse to +80 mV, a 5-ms interpulse to −80 mV, and a 40-ms test pulse to +10 mV. The percentage of I~Ba~ inhibited in the absence of a prepulse (−PP I~Ba~) or presence of a +80-mV prepulse (+PP I~Ba~) was determined according to \[(I~0−PP~ − I~−PP~)/I~0−PP~\] × 100, or \[(I~0+PP~ − I~+PP~)/I~0+PP~\] × 100, respectively, where I~0+PP~ and I~0−PP~ represent current amplitudes (controls) obtained with or without a prepulse in the absence of a compound, respectively. I~0−PP~ was normalized to I~0+PP~. I~+PP~ and I~−PP~ represent current amplitudes obtained with or without a prepulse in the presence of a compound, respectively. The VI fraction was defined as (+PP I~Ba~) × 100/(−PP I~Ba~), whereas the VD fraction was calculated as (−PP I~Ba~) − VI.

Membrane currents were filtered at 3 kHz and sampled at 10 kHz. Leak and capacitive currents were subtracted using a −P/4 pulse protocol. Peptides and various drugs were prepared from stock solutions, diluted to appropriate final concentration, and applied via perfusion in the bath solution. Data were stored digitally on a computer for further analysis. Current densities were calculated by dividing the normalized current amplitude by the cell capacitance measured at the start of each experiment.

In successive transfections, the magnitude of baclofen inhibition of I~Ba~ was routinely tested in HEK cells stably expressing Ca~v~2.1 or Ca~v~2.3 channels and coexpressing GABA~B~Rs. In ∼5% of all cells tested, I~Ba~ inhibition by baclofen was ≤25%. In such cases, the results were not included in the analysis or the experiment was discontinued. When evaluating the Vc1.1 concentration dependence of I~Ba~ inhibition, only a maximum of three different Vc1.1 concentrations per cell were tested because of the relatively long time needed to reach maximum inhibition with each Vc1.1 concentration.

Peptides, chemicals, and drugs
------------------------------

α-Conotoxins Vc1.1, cyclized-Vc1.1 (c-Vc1.1), and PeIA were synthesized as described previously ([@bib16], [@bib17]; [@bib22]). Synthetic Vc1.1 and PeIA are 16--amino acid residue peptides with a characteristic helical region and two disulfide bonds in a I--III, II--IV arrangement ([@bib16], [@bib17]; [@bib22]). c-Vc1.1 exhibits better properties than the linear Vc1.1 (also known as ACV1), including high chemical stability, resistance to cleavage by proteases, and improved potency to inhibit N-type VGCCs ([@bib17]). Most data on α-conotoxin effects on various Ca~v~2 channels were obtained using c-Vc1.1, unless otherwise noted. GABA, baclofen, guanosine 5′-\[β-thio\]diphosphate trilithium salt (GDP-β-S), and pertussis toxin (PTX) were purchased from Sigma-Aldrich. (2*S*)-3-\[\[(1*S*)-1-(3,4-dichlorophenyl)ethyl\]amino-2-hydroxypropyl\](phenylmethyl) phosphinic acid hydrochloride (CGP55845) and pp60c-Src peptide (521--533) were purchased from Tocris Bioscience.

c-Src phosphorylation site prediction
-------------------------------------

A publicly available catalog of phosphorylation motifs (<http://www.hprd.org/PhosphoMotif_finder>; [@bib4]) was used to identify Src kinase substrate motifs within Ca~v~2.1 and Ca~v~2.3 C-terminal regions corresponding to exon 37 (e37) of Ca~v~2.2 channel. This catalog does not use algorithms or computational strategies to predict phosphorylation but reports the presence of any literature-derived motifs.

Curve fitting and statistical analysis
--------------------------------------

Data analysis was performed in Clampfit 9.2 (Molecular Devices) and Origin 9.0 (Microcal Software Inc.). The voltage dependence of I~Ba~ activation was determined from I-V curves fitted to the following transform of a Boltzmann function: I~Ba~ = G~max~(V − V~rev~)/{1 + exp\[(V − V~0.5,act~)/k\]}, where V~rev~ is the extrapolated reversal potential, V is the membrane potential, I~Ba~ is the peak current elicited by the voltage pulse, G~max~ is the maximum conductance, V~0.5,act~ is the voltage for half-maximal current activation, and k is the slope factor ([@bib29]). Current amplitudes obtained in the presence of a compound (I) were normalized to current amplitudes obtained under control conditions (I~0~). Concentration--response curves were obtained by plotting averaged relative peak current amplitude (I/I~0~) against compound concentration and fitting the Hill equation I = I~0~{\[D\]^h^/(IC~50~^h^ + \[D\]^h^)} to resulting data, where I~0~ is the maximum peak current amplitude, \[D\] is the concentration of the compound (drug), IC~50~ is the half-maximal inhibitory concentration, and h is the Hill coefficient (slope). Concentration--response curves are interpreted as functional responses by a ligand (baclofen or c-Vc1.1) against a change in ligand concentration. Results shown in [Fig. 2 (B and C)](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"} were obtained by applying increasing concentrations of baclofen to the extracellular solution. Because baclofen inhibition of Ca~v~2.3 channels is irreversible, these experiments do not represent equilibrium steady-state measurements ([@bib15]).

Data are mean ± SEM (*n*, number of experiments). Statistical analyses were performed in Sigma Plot 11.0 (Systat Software, Inc.) using Student's *t* test for two groups or one-way ANOVA with Bonferroni post-hoc testing for multiple comparisons. When one-way ANOVA failed, Kruskal--Wallis one-way ANOVA on ranks with Tukey test for multiple comparisons was used. Differences were considered statistically significant at P \< 0.05.

Online supplemental material
----------------------------

Table S1 shows the parameters of the Boltzmann fits to I-V and G-V curves in Ca~v~2.1/GABA~B~R cells in the presence of 0.5 or 10 mM EGTA in the intracellular recording solution. Fig. S1 shows the voltage dependence of baclofen inhibition of Ca~v~2.3d channels in the presence of 0.5 or 10 mM EGTA in the intracellular recording solution. Whole-cell I~Ba~ was recorded from HEK cells transiently coexpressing wild-type Ca~v~2.3d or mutant Ca~v~2.3d (Y1765F) channels and GABA~B~Rs. The online supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.201311104/DC1>.

RESULTS
=======

Differential inhibition of Ca~v~2.3 and Ca~v~2.1 channels by α-conotoxin Vc1.1 via G protein--coupled GABA~B~Rs
---------------------------------------------------------------------------------------------------------------

We investigated VGCC modulation by baclofen and α-conotoxin Vc1.1 in HEK cells stably expressing Ca~v~2.1 (α~1A-2~) or Ca~v~2.3c (α~1E-c~) channels and transiently expressing GABA~B~Rs (Ca~v~2.1/GABA~B~R cells or Ca~v~2.3/GABA~B~R cells, respectively). [Fig. 1 (A--C)](#fig1){ref-type="fig"} shows typical examples of depolarization-activated whole-cell I~Ba~ in the absence or presence of 200 nM c-Vc1.1 or 50 µM baclofen. In Ca~v~2.1/GABA~B~R cells, c-Vc1.1 did not modulate I~Ba~ but inhibited I~Ba~ in Ca~v~2.3/GABA~B~R cells. The effect of c-Vc1.1 developed relatively slowly, reached maximum inhibition 3--7 min after the response started, and was irreversible ([Fig. 1 B](#fig1){ref-type="fig"}). The "linear" α-conotoxin Vc1.1 and α-conotoxin PeIA also inhibited depolarization-activated I~Ba~ in Ca~v~2.3/GABA~B~R cells ([Table 1](#tbl1){ref-type="table"}).

![Effects of α-conotoxin c-Vc1.1 and baclofen (bac) on stably expressed human Ca~v~2.1 (α~1A-2~) or human Ca~v~2.3c (α~1E-c~) channels in the presence of transiently expressed human GABA~B~R subunits R1 and R2 (GABA~B~R). (A and B) 50 µM baclofen inhibits Ca~v~2.1 or Ca~v~2.3c channel currents, whereas 200 nM c-Vc1.1 only inhibits Ca~v~2.3c currents. Bars indicate c-Vc1.1 or baclofen application. I~Ba~ was evoked by 150-ms depolarizations to 10 mV (Ca~v~2.3c) or 15 mV (Ca~v~2.1), applied every 10 s from an HP of −80 mV (voltage inset). Peak current amplitudes were plotted as a function of time. Representative I~Ba~ traces (right) are shown at the times indicated by lowercase letters. Horizontal dotted line represents zero-current level. Note that Ca~v~2.1 current inhibition by baclofen is reversible on washout (A), whereas baclofen or c-Vc1.1 irreversibly inhibits Ca~v~2.3c currents (B). (C) 50 µM baclofen inhibits I~Ba~ in Ca~v~2.3/GABA~B~R cells. Experimental procedures are similar to those in A or B.](JGP_201311104_Fig1){#fig1}

###### 

Summary of I~Ba~ inhibition by baclofen, GABA, or α-conotoxins in the presence or absence of GABA~B~Rs in HEK cells stably expressing human Ca~v~2.1 or Ca~v~2.3c channels

  Agonist            I~Ba~ inhibition (%)                             
  ------------------ ---------------------- ------- ----------------- -------
  Baclofen (50 µM)   39.9 ± 2.6 (17)        0 (5)   39.5 ± 4.3 (11)   0 (6)
  GABA (50 µM)       38.4 ± 2.7 (7)         ND      39.3 ± 4.1 (9)    ND
  Vc1.1 (200 nM)     0 (9)                  ND      25.5 ± 4.2 (9)    ND
  c-Vc1.1 (200 nM)   0 (10)                 0 (6)   34.8 ± 2.9 (16)   0 (5)
  PeIA (200 nM)      0 (3)                  ND      27.0 ± 3.0 (3)    ND

Values represent mean ± SEM; *n*, number of experiments in parentheses; ND, not determined.

These peptides have been shown to selectively inhibit high voltage--activated N-type calcium channels by acting as G protein--coupled GABA~B~R agonists in rat DRG neurons ([@bib13]; [@bib22]). Ca~v~2.1/GABA~B~R or Ca~v~2.3/GABA~B~R cells typically responded to baclofen, with relatively fast I~Ba~ inhibition that was completely reversible or weakly reversible/irreversible, respectively ([Fig. 1, A and C](#fig1){ref-type="fig"}, and [Table 1](#tbl1){ref-type="table"}). In most experiments, applying baclofen after c-Vc1.1 exposure further suppressed a small fraction (\<10%) of I~Ba~ in Ca~v~2.3/GABA~B~R cells. We determined the baclofen concentration dependence of I~Ba~ inhibition for Ca~v~2.1 and Ca~v~2.3 channels ([Fig. 2, B and D](#fig2){ref-type="fig"}), resulting in relationships described by the Hill equation ([Table 2](#tbl2){ref-type="table"}). 50 µM GABA also inhibited ∼40% of I~Ba~ in Ca~v~2.1/GABA~B~R and Ca~v~2.3/GABA~B~R cells and exhibited IC~50~ values similar to those obtained with baclofen ([Table 2](#tbl2){ref-type="table"}). The c-Vc1.1 concentration dependence of I~Ba~ inhibition in Ca~v~2.3/GABA~B~R cells ([Fig. 2 F](#fig2){ref-type="fig"}) resulted in IC~50~ and Hill coefficient values of 290 ± 0.8 pM and 0.61 ± 0.1, respectively, and defined c-Vc1.1 as a potent Ca~v~2.3 channel inhibitor ([Table 2](#tbl2){ref-type="table"}). [Fig. 2 (A and C)](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"} summarize the average I~Ba~ inhibition by baclofen, GABA, Vc1.1, c-Vc1.1, and PeIA in the absence and presence of GABA~B~Rs. These results demonstrate that GABA~B~R expression is needed for baclofen to inhibit Ca~v~2.1 and Ca~v~2.3 channels, and for c-Vc1.1 to inhibit Ca~v~2.3 channels. Moreover, the decreased response to baclofen after c-Vc1.1's effect is consistent with an overlap between the intracellular signaling mechanisms induced by these two compounds ([Figs. 1 B](#fig1){ref-type="fig"} and [2 E](#fig2){ref-type="fig"}).

![Stably expressed human Ca~v~2.1 (α~1A-2~) or human Ca~v~2.3c (α~1E-c~) channel inhibition by baclofen (bac) and α-conotoxin Vc1.1 in the absence and presence of transiently expressed human GABA~B~R. (A and C) Bar graphs showing average I~Ba~ inhibition through Ca~v~2.1 (A) or Ca~v~2.3c (C) channels by 50 µM baclofen, 200 nM Vc1.1, or 200 nM c-Vc1.1. Numbers in parentheses indicate the number of experiments. (E) Average I~Ba~ inhibited by 50 µM baclofen applied before or after 200 nM c-Vc1.1; "before c-Vc1.1" data are replotted from C. (B, D, and F) Concentration-dependent inhibition of I~Ba~ through Ca~v~2.1 and Ca~v~2.3c channels by baclofen (B and D) and Ca~v~2.3c channels by c-Vc1.1 (F). See IC~50~ values in [Table 2](#tbl2){ref-type="table"}.](JGP_201311104_Fig2){#fig2}

###### 

Summary of half-maximal inhibitory concentration (IC~50~) and Hill slope values in HEK cells stably expressing human Ca~v~2.1 or Ca~v~2.3c channels and transiently coexpressing GABA~B~Rs

  Agonist    Ca~v~2.1 and GABA~B~R   Ca~v~2.3c and GABA~B~R                                                         
  ---------- ----------------------- ------------------------ ----------------------------------------------------- -------------
             *nM*                                             *nM*                                                  
  Baclofen   470 ± 34 (5)            0.73 ± 0.05              330 ± 72 (7)                                          0.75 ± 0.14
  GABA       388 ± 17 (4)            0.76 ± 0.20              328 ± 102 (4)                                         0.75 ± 0.24
  c-Vc1.1    ---                     ---                      0.29 ± 0.08 (4--7)[a](#tblfn1){ref-type="table-fn"}   0.61 ± 0.14

Values represent mean ± SEM; *n*, number of experiments in parentheses; see details of the fitting procedure in Materials and methods.

Each data point ([Fig. 2 F](#fig2){ref-type="fig"}) was obtained from four to seven individual experiments.

Voltage dependence of GABA~B~R-mediated inhibition of Ca~v~2.1 and Ca~v~2.3 channels
------------------------------------------------------------------------------------

Direct VGCC inhibition by G protein--dependent inhibitory pathways involves VD Gβγ binding to the pore-forming subunit ([@bib6]; [@bib35]; [@bib38]). I-V relationships were recorded in the absence and presence of baclofen in Ca~v~2.1/GABA~B~R cells and Ca~v~2.3/GABA~B~R cells, or c-Vc1.1 in Ca~v~2.3/GABA~B~R cells. The biophysical properties of ion permeation through Ca~v~2.1 and Ca~v~2.3 channels stably expressed in HEK cells have been characterized previously ([@bib21]). We evaluated any depolarizing shift in the midpoint of activation (V~0.5,act~) of these channels, which may indicate the presence of direct Gβγ modulation, by fitting I-V relationships to a modified Boltzmann function (see Materials and methods; [Fig. 3 A](#fig3){ref-type="fig"}). Fits of the normalized I-Vs revealed that V~0.5,act~ shifted slightly from 6.18 ± 0.3 mV (*n* = 8; control) to 7.40 ± 0.58 mV (*n* = 8; baclofen), but the difference was not statistically significant (P = 0.083) in Ca~v~2.1/GABA~B~R cells. However, it should be noted that the inhibition of Ca~v~2.1/GABA~B~R cells by baclofen (31.1 ± 2.6%) is slightly less than the inhibition shown in [Fig. 2 A](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}. This is probably because of spontaneous I~Ba~ recovery from inhibition that occurred even in the continuous presence of baclofen and could cause the underestimation of the V~0.5,act~ positive shift in these experiments. To reduce the contribution of recovery in this process, we also investigated baclofen inhibition of I~Ba~ in Ca~v~2.1/GABA~B~R cells, evoked by voltage ramps. To assess any effect of divalent cation buffering on I-V relationships, we included 0.5 or 10 mM EGTA in the intracellular solution ([Fig. 4](#fig4){ref-type="fig"} and [Table S1](http://www.jgp.org/cgi/content/full/jgp.201311104/DC1){#supp1}). Voltage ramps in the absence and presence of baclofen resulted in V~0.5,act~ values similar to those obtained with voltage steps ([Fig. 3 A](#fig3){ref-type="fig"}). In Ca~v~2.3/GABA~B~R cells, the V~0.5,act~ values were −3.44 ± 0.67 mV (*n* = 8) in the presence of baclofen and −0.44 ± 0.46 mV (*n* = 7) for c-Vc1.1 compared with 0.67 ± 0.24 mV (*n* = 15; control). In these experiments, baclofen caused a significant hyperpolarizing shift of V~0.5,act~ (P \< 0.001 vs. control; one-way ANOVA). However, V~0.5,act~ was not altered by c-Vc1.1 (P = 0.223).

![Voltage dependence of Ca~v~2.1 (α~1A-2~) and stably expressed Ca~v~2.3c channel inhibition via GABA~B~R activation. (A) I-V relationships in Ca~v~2.1/GABA~B~R cells (left) in the absence (control) and presence of 50 µM baclofen, and in Ca~v~2.3/GABA~B~R cells (right) in the absence (control) or presence of 50 µM baclofen or 200 nM c-Vc1.1. (Insets) Voltage protocol and representative normalized current traces (only 23 ms of the 100-ms traces are shown). See Table S1 for V~0.5,act~ values. (B) Ca~v~2.1 channel inhibition via GABA~B~R is VD, whereas that of Ca~v~2.3c is VI. Representative 15-mV depolarization-activated inward I~Ba~ from Ca~v~2.1/GABA~B~R cells (top) in the absence (control) or presence of 50 µM baclofen, without (−PP) or after the application of a depolarizing prepulse to +80 mV (+PP). (Bottom) Representative 10-mV depolarization-activated I~Ba~ from Ca~v~2.3/GABA~B~R cells in the absence (control) or presence of 50 µM baclofen or 200 nM c-Vc1.1. Dotted lines indicate zero-current level. The voltage protocol (top inset) is described in Materials and methods. (Right) Summary of I~Ba~ inhibition in the absence or presence of a prepulse. Data are mean ± SEM (paired Student's *t* test; \*, P \< 0.001 vs. control \[−PP\] in Ca~v~2.1/GABA~B~R cells). The number of experiments is in parentheses. VD, voltage dependent; VI, voltage independent.](JGP_201311104_Fig3){#fig3}

![Effects of baclofen on stably expressed human Ca~v~2.1 (α~1A-2~) channels in the presence of transiently expressed human GABA~B~Rs (Ca~v~2.1/GABA~B~R cells). (A) Baclofen-inhibition of I~Ba~ in the presence of 0.5 mM EGTA in the intracellular recording solution. 50 µM baclofen reversibly inhibited I~Ba~ by 38.5 ± 3.9% (*n* = 5). (Left) Representative currents in the absence (control) and presence of baclofen, elicited by voltage ramps to +50 mV from an HP of −80 mV at 0.1 Hz. Dotted line represents zero-current level. (Middle) I-V relationships in the absence and presence of baclofen. Current amplitudes were determined from voltage ramps at selected membrane potentials (V~m~). Solid lines are fits of the modified Boltzmann equation to normalized I-V relationships (see Materials and methods). (Right) Voltage dependence of activation determined from G-V relationships. Relative conductance (G/G~max~) was calculated as I~Ba~/(V~m~ − V~rev~), where V~rev~ is the reversal potential of the whole-cell current and plotted as a function of V~m~. The normalized G-V relationships were fitted with a Boltzmann function, G = G~max~/(1 + exp((V~0.5,act~ − V~m~)/k)), where V~0.5,act~ is the potential at which the conductance is half-maximally activated, and k is the slope factor. (B) Similar experimental procedures and data representation as shown in A, with 10 mM EGTA in the intracellular recording solution. Baclofen reversibly inhibited I~Ba~ by 41.8 ± 4.7% (*n* = 6). See Table S1 for V~0.5,act~ (voltage for half-maximal current activation) and k (slope factor) values resulting from experiments shown in A and B.](JGP_201311104_Fig4){#fig4}

We evaluated if baclofen inhibition of I~Ba~ in Ca~v~2.1/GABA~B~R and Ca~v~2.3/GABA~B~R cells, and c-Vc1.1 inhibition of I~Ba~ in Ca~v~2.3/GABA~B~R cells, could be reversed by strong depolarization. A +80-mV prepulse of 20-ms duration was applied before the test pulse to relieve any VD component of G protein--mediated I~Ba~ inhibition ([Fig. 3 B](#fig3){ref-type="fig"}). In both cells, shortening (10 ms) or prolonging (50 ms) the prepulse or interpulse (10 ms) did not change I~Ba~ facilitation. Applying +120-mV prepulses only added ∼5% facilitation in Ca~v~2.1/GABA~B~R cells, without changing I~Ba~ relief with Ca~v~2.3/GABA~B~R cells (not depicted). The inhibitory effect of baclofen was associated with a large (73 ± 4%) VD component in Ca~v~2.1/GABA~B~R cells. In contrast, the effect of baclofen and Vc1.1 was solely mediated by a VI pathway in Ca~v~2.3/GABA~B~R cells, which clearly indicates that intracellular signaling does not involve the classical G protein βγ dimer (Gβγ) binding to the pore-forming Ca~v~2.3 channel subunit. Alternatively, Gβγ could bind with high affinity to the Ca~v~2.3 channel in a VI manner.

c-Vc1.1 inhibition of Ca~v~2.3 channels involves Gα~i/o~ subunits and c-Src kinase
----------------------------------------------------------------------------------

We evaluated the VI pathway leading to Ca~v~2.3 channel modulation by determining the fraction of I~Ba~ that could be inhibited under various experimental conditions ([Fig. 5](#fig5){ref-type="fig"}). In HEK cells stably expressing Ca~v~2.3c channels (Ca~v~2.3 cells) or Ca~v~2.3 cells coexpressing GABA~B~R R2 subunits, neither 200 nM c-Vc1.1 nor 50 µM baclofen inhibits I~Ba~, indicating that a fully functional GABA~B~R heterodimer is needed for proper signaling. In Ca~v~2.3/GABA~B~R cells, the selective GABA~B~R antagonist CGP55845 (1 µM) did not change I~Ba~ amplitude or kinetics but strongly antagonized I~Ba~ inhibition by c-Vc1.1 and reduced the effect of baclofen by ∼60% compared with control. This confirmed that GABA~B~R needed to be activated for c-Vc1.1 and baclofen inhibitory effects to occur. When the hydrolysis-resistant GDP analogue GDP-β-S (500 µM) was added to the intracellular recording solution, Vc1.1 and baclofen inhibitory effects were almost identically reduced. Overnight treatment with 1 µg/ml PTX abolished c-Vc1.1 and baclofen inhibitory pathway(s) in Ca~v~2.3/GABA~B~R cells, suggesting that the effects were mediated by G~i~ and/or G~o~ proteins.

![c-Vc1.1 and baclofen inhibit stably expressed Ca~v~2.3c calcium channels via G protein--coupled GABA~B~Rs. Neither compound inhibits I~Ba~ in the absence of GABA~B~Rs (see also [Fig. 2 C](#fig2){ref-type="fig"}) or the absence of GABA~B~R R1 subunits. 1 µM CGP55845 or 500 µM GDP-β-S significantly reduces c-Vc1.1 and baclofen responses, respectively. A 24-h pretreatment with 1 µg/ml PTX abolishes the effect of c-Vc1.1 or baclofen. Data are mean ± SEM (one-way ANOVA; \*, P \< 0.001 vs. controls; Ca~v~2.3/GABA~B~R cells with c-Vc1.1 or baclofen, respectively).](JGP_201311104_Fig5){#fig5}

We previously showed that Vc1.1 inhibition of N-type (Ca~v~2.2) calcium channel currents can be blocked by a phosphorylated synthetic pp60c-Src peptide ([@bib13]). This is probably a result of pp60c-Src binding to the SH2 domain of native c-Src protein in rat DRG neurons. Therefore, we examined in more detail the role of c-Src in the GABA~B~R-mediated Ca~v~2.1 or Ca~v~2.3 channel inhibition by baclofen and c-Vc1.1 in the HEK expression system ([Fig. 6](#fig6){ref-type="fig"}). We changed endogenous HEK cell c-Src protein levels ([@bib40]) by including cDNAs of wild-type or mutant c-Src in our expression system. In Ca~v~2.1/GABA~B~R cells, wild-type c-Src protein overexpression or inclusion of the pp60c-Src peptide (50 µM) in the intracellular solution did not affect baclofen inhibition of I~Ba~. However, in Ca~v~2.3/GABA~B~R cells, wild-type c-Src protein overexpression dramatically increased the fraction of I~Ba~ inhibited by c-Vc1.1 compared with control.

![The role of c-Src proteins in GABA~B~R-mediated inhibition by c-Vc1.1 in HEK cells stably expressing human Ca~v~2.3c channels and GABA~B~Rs. (A) Time course of I~Ba~ through Ca~v~2.3c channels in the absence (control) and presence of 200 nM c-Vc1.1 or 50 µM baclofen. Bars indicate c-Vc1.1 or baclofen application. Overexpression of wild-type c-Src protein increases the I~Ba~ fraction inhibited by c-Vc1.1 (top). Overexpression of the double mutant c-Src (K295R/Y527F) (middle) or pretreatment with the phosphorylated pp60c-Src peptide (50 µM) (bottom) abolishes the effect of c-Vc1.1 and reduces baclofen inhibition of I~Ba~, respectively. Representative current traces (right) are shown at the times indicated by lowercase letters (see [Fig.1 B](#fig1){ref-type="fig"} for control). I~Ba~ was evoked by 150 ms, 0.1-Hz depolarizations to 10 mV, from an HP of −80 mV (voltage inset). Peak current amplitudes were plotted as a function of time. Horizontal dotted lines indicate zero-current levels. (B) Average data (±SEM) of I~Ba~ inhibition by c-Vc1.1 or baclofen after pp60c-Src peptide (50 µM) pretreatment or wild-type c-Src coexpression in Ca~v~2.1/GABA~B~R or Ca~v~2.3/GABA~B~R cells, respectively, or double mutant c-Src (K295R/Y527F) coexpression in Ca~v~2.3/GABA~B~R cells (\*, P \< 0.001 vs. controls; one-way ANOVA). The number of experiments is in parentheses.](JGP_201311104_Fig6){#fig6}

To further evaluate the effect of c-Src on Ca~v~2.3/GABA~B~R cells, we overexpressed the K295R/Y527F c-Src double mutant, which is kinase inactive and functions as a dominant-negative inhibitor of wild-type c-Src ([@bib30]). This construct reduced the effect of baclofen compared with control and abolished c-Vc1.1's inhibitory effect. The effect of K295R/Y527F c-Src was recapitulated with the pp60c-Src peptide, suggesting that c-Src kinase activity is needed for VI inhibition of I~Ba~ by c-Vc1.1 and baclofen ([Fig. 6, A and B](#fig6){ref-type="fig"}).

Tyrosines 1761 and 1765 are needed in the C terminus for c-Src phosphorylation of Ca~v~2.3 channels
---------------------------------------------------------------------------------------------------

Alternative splicing of Ca~v~2.1, Ca~v~2.2, and Ca~v~2.3 genes creates channels with distinct kinetic, pharmacological, and modulatory properties ([@bib10]; [@bib7]; [@bib27]; [@bib32]). It has been reported that GPCR-mediated inhibition of the nociceptor-specific Ca~v~2.2\[e37a\] channel occurred via VD and VI pathways. In HEK cells coexpressing GABA~B~Rs and Ca~v~2.2\[e37a\] channels, the baclofen-induced VI component required a tyrosine (Y) residue in e37a to be phosphorylated ([@bib52]).

Alignment of the Ca~v~2.2 channel e37a and e37b regions with the corresponding e37 regions in human Ca~v~2.3c, Ca~v~2.3d, and Ca~v~2.1 (α~1A-2~ or α~1A-5~), and rabbit Ca~v~2.1 channels, indicated a degree of structural conservation and the presence of tyrosine kinase consensus sites ([Fig. 7 A](#fig7){ref-type="fig"}). We hypothesized that Y residues within e37 at the proximal C terminus in Ca~v~2.3 channels could serve as substrates for phosphorylation by c-Src. Using a publicly available catalog of phosphorylation motifs ([@bib4]), we identified putative c-Src kinase phosphorylation sites in human Ca~v~2.3 and rabbit Ca~v~2.1, but not in human Ca~v~2.1 channels. In both human Ca~v~2.3c and Ca~v~2.3d splice variants, the Y1761 and Y1675 (as numbered in GenBank accession no. [L29385](L29385)) are followed by a threonine (T) or glutamic acid (E), respectively, as are potential substrates for Src kinases. Remarkably, in rabbit Ca~v~2.1, the second Y residue followed by alanine (A) also represents a Src motif described in the literature. In contrast, in the human Ca~v~2.1 splice variants α~1A-2~ or α~1A-5~, the consensus Y1851 and Y1855 residues (as numbered in RefSeq accession no. [NM_001174080](NM_001174080)) lack the neighboring amino acids that are needed to generate known Src kinase substrates for phosphorylation ([@bib4]).

![Kinase-dependent phosphorylation of the intracellular proximal C terminus is needed for VI Ca~v~2.3 channel inhibition by c-Vc1.1. (A) Amino acid sequence alignments of e37 regions in splice variants of Ca~v~2.2, Ca~v~2.1, and Ca~v~2.3 and mutant Ca~v~2.1 and Ca~v~2.3 genes. Y (red), followed by A, E, or T (orange), is shown as a possible substrate for c-Src phosphorylation. (Right) Proposed model for c-Vc1.1--induced intracellular signaling leading to Ca~v~2 channel inhibition. Asterisk indicates phosphorylation. (B) Average I~Ba~ inhibition in the presence of 200 nM c-Vc1.1 or 50 µM baclofen in HEK 293T cells transiently cotransfected with wild-type human Ca~v~2.3d (α~1E-d~) and Ca~v~2.3c (α~1E-c~); Ca~v~2.1 (α~1A-5~); rabbit Ca~v~2.1 channel subunits; human e37 mutants Ca~v~2.3d (Y1761F), Ca~v~2.3d (Y1765F), Ca~v~2.3c (Y1761F), Ca~v~2.3c (Y1765F), Ca~v~2.1 (α~1A-5~) (L1852T), or Ca~v~2.1 (α~1A-5~) (Q1852E); auxiliary human Ca~v~ channel subunits α~2b~δ-1 and β~3~; and human GABA~B~R subunits. Representative normalized I~Ba~ traces (current insets) of wild-type or mutant channels are shown in the absence (control) or presence of 200 nM c-Vc1.1 or 50 µM baclofen (only 65 ms of the 150-ms current traces are plotted). I~Ba~ was evoked by depolarizations to +10 mV (Ca~v~2.3c) or 15 mV (Ca~v~2.1), applied at 0.1 Hz from an HP of −80 mV. Dotted lines indicate zero-current levels. Bar graphs show mean ± SEM; *n*, number of experiments in parentheses. Labels a, b, and c denote statistically significant differences between various mutants and control; NS, not significantly different from wild-type modulation. See [Table 3](#tbl3){ref-type="table"} for statistical evaluation of the data.](JGP_201311104_Fig7){#fig7}

We conducted a structure--function study in the e37 region to identify the amino acid residues responsible for the different sensitivity to c-Vc1.1. We also tested their contribution to c-Src--mediated inhibition in HEK cells transiently coexpressing GABA~B~Rs and transiently expressing Ca~v~2.3c or Ca~v~2.3d splice variants, or human or rabbit Ca~v~2.1 channels. In patch-clamp experiments, 200 nM c-Vc1.1 inhibited human Ca~v~2.3c and Ca~v~2.3d channels but did not affect human Ca~v~2.1 (α~1A-5~) ([Fig. 7 B](#fig7){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). This confirmed previous results in HEK cells stably expressing Ca~v~2.1 (α~1A-2~) or Ca~v~2.3c channels in the presence of GABA~B~Rs ([Figs. 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). In all experiments, 50 µM baclofen inhibited I~Ba~. As predicted, c-Vc1.1 also inhibited rabbit Ca~v~2.1 channels, likely because of the presence of a putative c-Src phosphorylation site in the C terminus ([Fig. 7 A](#fig7){ref-type="fig"}).

###### 

Summary of I~Ba~ inhibition by baclofen and c-Vc1.1 in HEK 293T cells transiently coexpressing GABA~B~Rs and Ca~v~2.1 or Ca~v~2.3 channels

  Ca~v~2 channel             I~Ba~ inhibition (%)                               
  -------------------------- -------------------------------------------------- --------------------------------------------------
  Human Ca~v~2.3d            23 ± 2.9 (8)                                       33.1 ± 1.8 (8)
  Human Ca~v~2.3d (Y1761F)   1.7 ± 0.3 (11)[a](#tblfn2){ref-type="table-fn"}    21.9 ± 1.8 (11)[c](#tblfn4){ref-type="table-fn"}
  Human Ca~v~2.3d (Y1765F)   11.3 ± 3.0 (10)[b](#tblfn3){ref-type="table-fn"}   ^NS^28.9 ± 2.7 (10)
  Human Ca~v~2.3c            28.0 ± 4.0 (10)                                    44.0 ± 3.0 (10)
  Human Ca~v~2.3c (Y1761F)   0.37 ± 0.3 (8)[a](#tblfn2){ref-type="table-fn"}    14.6 ± 1.8 (8)[c](#tblfn4){ref-type="table-fn"}
  Human Ca~v~2.3c (Y1765F)   15.0 ± 3.2 (10)[b](#tblfn3){ref-type="table-fn"}   28.9 ± 2.7 (10)[d](#tblfn5){ref-type="table-fn"}
  Human Ca~v~2.1             0 (8)                                              44.4 ± 1.9 (9)
  Human Ca~v~2.1 (L1852T)    7.2 ± 1.4 (8)[a](#tblfn2){ref-type="table-fn"}     ^NS^50.6 ± 2.8 (8)
  Human Ca~v~2.1 (Q1856E)    6.6 ± 1.7 (8)[b](#tblfn3){ref-type="table-fn"}     ^NS^47.9 ± 3.0 (8)
  Rabbit Ca~v~2.1            ^\#^20.0 ± 4.0 (7)                                 ^\#^50.0 ± 5.0 (8)

Values represent mean ± SEM; *n*, number of experiments in parentheses. NS, not significantly different from wild-type modulation. One-way ANOVA with Bonferroni post-hoc testing was used to test for statistically significant differences except when comparing the effect of c-Vc1.1 on wild-type or mutant Ca~v~2.1 (one-way ANOVA on ranks with Tukey test). Data marked with a hash symbol were not included in the statistical analysis. Note that the percentage of inhibition with transiently expressed human Ca~v~2.1 or Ca~v~2.3c channels and transiently coexpressed GABA~B~Rs (above) is similar (within the statistical margin of error) to that obtained with stably expressed human Ca~v~2.1 or Ca~v~2.3c channels in the presence of transiently coexpressed GABA~B~Rs (see [Table 1](#tbl1){ref-type="table"}).

P \< 0.001 versus Ca~v~2.3d with c-Vc1.1; P \< 0.001 versus Ca~v~2.3c with c-Vc1.1; and P = 0.002 versus human Ca~v~2.1 with c-Vc1.1.

P = 0.003 versus Ca~v~2.3d with c-Vc1.1; P = 0.008 versus Ca~v~2.3c with c-Vc1.1; and P = 0.002 versus human Ca~v~2.1 with c-Vc1.1.

P = 0.003 versus Ca~v~2.3d with baclofen and P \< 0.001 versus Ca~v~2.3c with baclofen.

P \< 0.001 versus Ca~v~2.3c with baclofen.

Mutational analyses of the e37 region in the proximal C termini of Ca~v~2.3d or Ca~v~2.3c demonstrated that the Y1761F mutation completely abolished c-Vc1.1 inhibition of I~Ba~, and the Y1765F mutation significantly reduced the c-Vc1.1 inhibition ([Fig. 7 B](#fig7){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). These results suggest that tyrosines 1761 and 1765 are critical for mediating the effects of Vc1.1. Interestingly, these mutants, except the Ca~v~2.3d (Y1765F), also reduced baclofen inhibition of I~Ba~, which indicates that these Y residues are also involved in baclofen signaling. We explored how mutation affects the VI component of inhibition, in the absence and presence of a depolarizing prepulse, via baclofen inhibition of I~Ba~ through Ca~v~2.3d (Y1765F) channels. Experiments were performed with either 0.5 or 10 mM EGTA in the intracellular recording solution to (a) identify any effects of intracellular divalent cations on I~Ba~ facilitation ([@bib67]), and (b) rule out modulation by phospholipids ([@bib23]) ([Fig. S1](http://www.jgp.org/cgi/content/full/jgp.201311104/DC1){#supp2}). The results showed that the effect of baclofen was solely mediated by a VI pathway, independent of a classical Gβγ binding.

We also generated human Ca~v~2.1 (α~1A-5~) (L1852T) and Ca~v~2.1 (α~1A-5~) (Q1856E) channel mutants. Remarkably, the introduced putative c-Src phosphorylation sites conveyed sensitivity to c-Vc1.1 in these channels. Baclofen modulation was not affected by the Ca~v~2.1 (L1852T) or Ca~v~2.1 (Q1856E) channel mutants ([Fig. 7 B](#fig7){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). Collectively, these data suggest that specific c-Src phosphorylation sites in the C terminus are needed for α-conotoxin c-Vc1.1 inhibition of Ca~v~2.3 and Ca~v~2.1 channels. However, it remains possible that other residues are also involved in mediating baclofen's inhibition of Ca~v~2.3 channels.

DISCUSSION
==========

In this study, we efficiently reconstituted human Ca~v~2.1 and Ca~v~2.3 channel modulation via human G protein--coupled GABA~B~Rs. Baclofen, a GABA~B~R agonist, inhibited I~Ba~ through both channels; however, α-conotoxin Vc1.1 only inhibited Ca~v~2.3 channels. The effect of Vc1.1 on Ca~v~2.3 channels was completely VI and depended on the presence of specific c-Src phosphorylation sites in the C terminus of the human α~1E~ (Ca~v~2.3). These results define Ca~v~2.3 channels as new targets for analgesic α-conotoxins.

Ca~v~2 channels and chronic pain
--------------------------------

It is well established that Ca~v~2.2 channel inhibition by antagonists or via GPCRs produces analgesia in animals and humans ([@bib2]). GABA~B~R-mediated inhibition of Ca~v~2.1 or Ca~v~2.2 channels in various neurons is well documented ([@bib18]; [@bib44]; [@bib37]) and has been shown to involve VD and VI second messenger pathways ([@bib25]; [@bib24]). We showed that a subset of α-conotoxins, including Vc1.1, also selectively inhibit Ca~v~2.2 channels by acting as G protein--coupled GABA~B~R agonists ([@bib13]; [@bib12]; [@bib17]; [@bib22]). This mechanism may help relieve nerve injury--induced neuropathic pain ([@bib36]).

Studies involving pharmacological and genetic approaches have also established Ca~v~2.3 channels as potential targets for drugs that treat chronic pain ([@bib53]; [@bib51]). The anti-nociceptive role of Ca~v~2.3 channels was demonstrated in rat dorsal horn neurons ([@bib41]), and their inhibition was associated with high efficiency opioid therapy without tolerance ([@bib64]). Ca~v~2.3 channels are ubiquitously expressed in the central and peripheral nervous systems, but their physiological roles and modulation is not well understood. They typically conduct a small proportion of whole-cell Ca^2+^ current and are difficult to isolate in neurons ([@bib56]).

Baclofen and α-conotoxin Vc1.1 differentially inhibit Ca~v~2.1 and Ca~v~2.3 channels
------------------------------------------------------------------------------------

Our results demonstrate that baclofen or GABA inhibits I~Ba~ to a similar extent in Ca~v~2.1/GABA~B~R and Ca~v~2.3/GABA~B~R cells ([Figs. 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Throughout this study, we used cells with similar electrophysiological characteristics and applied supra-maximal doses of baclofen (50 µM) or c-Vc1.1 (200 nM) to make sure receptors were fully activated and rule out the possibility that differences were caused by cell variability.

In Ca~v~2.1 channel--expressing cells, baclofen inhibition was VD and could be relieved by a strong depolarizing prepulse, reflecting transient dissociation of G protein βγ subunits from the channel. The 20-ms prepulses and 5-ms interpulses were considered suitable for VD I~Ba~ relief in Ca~v~2.1 channels ([@bib20]). Our results on the voltage dependence of inhibition are consistent with previous studies demonstrating baclofen inhibition of Ca~v~2.1 channels in adrenal chromaffin cells and cerebellar Purkinje neurons ([@bib44]; [@bib20]). We did not analyze the time course of I~Ba~ activation in the presence of baclofen or c-Vc1.1 in Ca~v~2.1/GABA~B~R or Ca~v~2.3/GABA~B~R cells. However, in Ca~v~2.1/GABA~B~R cells, the time course of I~Ba~ activation considerably slowed in the presence of baclofen when compared with control. This is a hallmark of VD Gβγ binding to the α~1A~ (Ca~v~2.1) subunit ([Fig. 3 B](#fig3){ref-type="fig"}). Interestingly, baclofen only caused a small and statistically insignificant shift of the I-V and G-V relationships in Ca~v~2.1/GABA~B~R cells ([Figs. 3 A](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), which was independent of the intracellular EGTA concentration. [@bib9] also reported a similar slight positive shift of the µ opioid receptor--activated Ca~v~2.1 channel I-V relationship, suggesting possible differences between Ca~v~2.1 and Ca~v~2.2 channel--modulating membrane-delimited pathways. In Ca~v~2.3/GABA~B~R cells, the time course of I~Ba~ activation in the presence of baclofen or c-Vc1.1 seemed unaffected. In these cells, c-Vc1.1 did not affect the I-V relationship, but baclofen caused a hyperpolarizing I-V shift, which suggests that there may be an additional signaling mechanism. Our results show that neither baclofen nor Vc1.1 elicits VD inhibition of Ca~v~2.3 channels via GABA~B~Rs. However, it has been shown that the rat brain α1E~long~ splice variant could be inhibited in a VD manner via D2 dopamine receptors ([@bib46]). Our alignment of the human α~1E-c~ or α~1E-d~ and rat α1E~long~ splice variants (not depicted) indicate that the N-terminal sequence responsible for VD inhibition of rat α1E~long~ variant is present in human α~1E-c~ and α~1E-d~. Therefore, future experiments should determine whether or not human Ca~v~2.3 channels can be inhibited via D2 receptors in a VD manner. VD modulation may depend on the type of GPCR and specific signal transduction mechanism elicited by the GPCR-specific ligand.

The VI pathway leading to Ca~v~2.3 channel inhibition by baclofen or c-Vc1.1 could be disrupted by GDP-β-S, a GDP analogue that keeps Gα permanently associated with Gβγ. In all cases, PTX treatment abolished baclofen and c-Vc1.1 inhibition of I~Ba~, indicating that GABA~B~Rs couple with G proteins of the G~i~/G~o~ superfamily in cells expressing Ca~v~2.3 channels ([Fig. 5](#fig5){ref-type="fig"}). Analysis of the VI pathway in Ca~v~2.3/GABA~B~R cells indicated that signaling mechanisms that contribute to Ca~v~2.3 channel inhibition, downstream of G protein subunits, involve c-Src kinase activation. For example, wild-type c-Src overexpression increased I~Ba~ inhibition, whereas the dominant-negative double mutant c-Src or the pp60c-Src peptide abolished c-Vc1.1 inhibition of I~Ba~ ([Fig. 6](#fig6){ref-type="fig"}). This suggested that Ca~v~2.3 channels are a potential c-Src substrate. It has been demonstrated that certain protein tyrosine kinases can be direct effectors of G proteins ([@bib8]), and GABA inhibition of Ca~v~2.2 channels involves direct Gα~o~ activation of Src kinase ([@bib24]). However, further studies are needed to elucidate whether baclofen or Vc1.1 inhibition of Ca~v~2.3 channels involves direct G~i~/G~o~ activation of c-Src.

In Ca~v~2.1 and Ca~v~2.2 channels, intracellular N and C termini and cytoplasmic loops connecting domains I--IV have been shown to interact with other proteins and are targeted by second messenger pathways, including phosphorylation by kinases ([@bib66]). Many of these interaction or modulatory sites can also be identified in Ca~v~2.3 channels ([@bib56]). Furthermore, alternative splicing, recognized as a mechanism for creating functional diversity in VGCCs ([@bib32]), results in a series of Ca~v~2.3 splice variants ([@bib62]) with similar biophysical properties ([@bib49]). Of these, Ca~v~2.3c represents the major neuronal type variant, which is dominantly expressed in the adult central nervous system ([@bib56]), whereas Ca~v~2.3d, the variant cloned from human fetal brain ([@bib55]), shows minor in vivo expression in the adult brain ([@bib49]). Interestingly, the endocrine splice variant Ca~v~2.3e was also identified in nociceptive trigeminal ganglion and DRG neurons together with Ca~v~2.3a ([@bib27], [@bib28]). Importantly, the e37 region containing the putative c-Src phosphorylation sites can be identified in all Ca~v~2.3 splice variants.

There is evidence of multiple Src interaction sites in various VGCCs. For example, Src interacts with both the II--III linker and C-terminal tail regions of the L-type Ca^2+^ channel α1c subunit ([@bib26]). c-Src kinases also appear to be pre-associated with N-type VGCCs, efficiently modulating their function ([@bib54]). In addition, c-Src kinases have been implicated in the GABA~B~R-mediated inhibition of Ca~v~2.2 channels by baclofen ([@bib52]) and Vc1.1 ([@bib13]).

To date, GABA~B~R-mediated modulation of Ca~v~2.3 channels has not been reconstituted in expression systems, and c-Src phosphorylation of Ca~v~2.3 channels has not been demonstrated. Conserved Y residues within the e37 region can be identified across all Ca~v~2 family members and appear to be key substrates for phosphorylation by various tyrosine kinases. Our analysis of the e37 regions in Ca~v~2.1 and Ca~v~2.3 channels predicted Src kinase motifs in human Ca~v~2.3 channels. These motifs were absent in human Ca~v~2.1 ([Fig. 7](#fig7){ref-type="fig"}). Although phosphorylation site prediction can be error prone, it is a useful tool to determine whether e37 regions contain sequence contexts typical of c-Src motifs described previously in the literature ([@bib4]). It is generally accepted that the amino acid sequence motif around the tyrosine residue and three-dimensional structure of the substrate proteins contribute to phosphorylation site specificity ([@bib48]). Our structure--function studies confirmed that Y\[A/E/T\] sequences are the likely c-Src phosphorylation substrates and represent key switches for the molecular mechanisms involved. The lack of any effect of Vc1.1 on human Ca~v~2.1 channels agrees with the absence of a c-Src motif in the e37 region and marginal VI component in cells expressing these channels. Interestingly, c-Src motif Y\[K\] can also be identified in the Ca~v~2.2\[e37a\] channel, whereas such a motif is absent in Cav2.2\[e37b\]. Therefore, further studies are required to dissect the effects of Vc1.1 on Ca~v~2.2 channel splice variants. Our results also suggest that the effects of baclofen on Ca~v~2.3 channels are, at least partially, controlled by c-Src phosphorylation. Given that PTX completely abolishes the inhibition by baclofen, an additional PTX-sensitive pathway is probably also involved. Future studies should be aimed at directly correlating Ca~v~2.3 channel phosphorylation and dephosphorylation with inhibition and (the absence of) recovery, respectively. Clearly, further experiments are also needed to confirm that c-Src kinase directly phosphorylates Ca~v~2.3 channels in vivo.

Therapeutic implications of Ca~v~2.3 channel inhibition
-------------------------------------------------------

Few studies have examined Cav2.3 (R-type) channel modulation in neurons, where a combination of specific inhibitors is needed to completely block various VGCCs while preserving the R-type calcium channel. In thalamocortical neurons, R-type current modulation by baclofen has been demonstrated and could be antagonized by CGP55845 ([@bib33]). In rat DRG neurons, we also observed R-type current inhibition by baclofen in the presence of specific L-, N- and P/Q-type channel blockers (not depicted). However, further studies are needed to demonstrate what contribution the R-type current component makes to the whole-cell calcium conductance inhibited by Vc1.1 in nociceptive neurons.

GABA~B~R activation produces anti-nociceptive effects in animal models of acute or chronic pain ([@bib47]; [@bib11]). Baclofen is mainly injected into the spine to manage spasticity and neuropathic pain and as an adjuvant analgesic for relieving cancer pain ([@bib68]; [@bib65]). Its oral dose must be carefully regulated because of possible side effects. Vc1.1 does not compete with baclofen for binding to receptors, but it targets the interface between the GABA~B~R ectodomains (see [@bib1]). Vc1.1 was tested in human clinical trials, but its development was discontinued because of its lack of potency at human α9α10 nicotinic acetylcholine receptor, which was proposed to be the molecular target ([@bib42]). However, with the emergence of new α-conotoxin--based pharmacological tools that act on neuronal VGCCs via the GABA~B~R, its development is likely to resume. It remains to be established if analgesic α-conotoxins can be used as specific Ca~v~2.2\[e37a\] and Ca~v~2.3 channel inhibitors for the treatment of chronic pain.

In conclusion, we identified a previously unrecognized mechanism of α-conotoxin Vc1.1 and baclofen inhibition of Ca~v~2.3 channels that involves GABA~B~Rs. We systematically examined the intracellular pathways and elucidated the molecular details that determine c-Src phosphorylation of the Ca~v~2.1 and Ca~v~2.3 channel C termini. Although the physiological significance of kinase-mediated Ca~v~2.3 channel inhibition is unclear, it may have long-term influence over Ca^2+^-dependent intracellular signaling, exocytosis, and/or gene transcription in neurons.
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